Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status
Authors:
- Min-Jee KimMKMin-Jee Kim
- Myung-Seo KiMKMyung-Seo Ki
- Karham KimKKKarham Kim
- Hyun-Jeong ShimHSHyun-Jeong Shim
- Jun-Eul HwangJHJun-Eul Hwang
- Woo-Kyun BaeWBWoo-Kyun Bae
- Ik-Joo ChungICIk-Joo Chung
- Dong-Hoon LeeDLDong-Hoon Lee
- Joon-Kyoo LeeJLJoon-Kyoo Lee
- Tae-Mi YoonTYTae-Mi Yoon
- Sang-Chul LimSLSang-Chul Lim
- Woong-Ki ChungWCWoong-Ki Chung
Open Access
- 7 November 2014
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-11
Abstract
Oropharyngeal cancer (OPC) associated with human papilloma virus (HPV OPC) shows better treatment outcomes than non-HPV OPC. We investigated the expression of p53, β-tubulin, bcl-2 and ERCC 1, which are well-known biomarkers to predict the chemotherapy response, according to HPV status in OPC patients. Patients who treated with at least 2 cycles of induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced oropharyngeal cancer were reviewed. HPV PCR and immunohistochemical stain was done in paraffin embedded tumor tissue and evaluated the relation with the chemotherapy response and survival outcomes according to HPV status. Seventy-four patients were enrolled for this study and all patients received induction chemotherapy with docetaxel, 5-FU and cisplatin. After induction chemotherapy, complete response (CR) was shown in 22 patients (30%) and partial response (PR) in 46 patients (62%). HPV + was detected in 21 patients (28%), while 35 patients (47%) showed p16+ expression by IHC analysis. p16 positive patients showed better overall response, PFS and OS than p16 negative patients. p53 and class III beta-tubulin expression were significantly higher in HPV- and p16- than HPV + and p16+ patients. Conversely, bcl-2 expression was greater in HPV + or p16+ than HPV- or p16- patients. ERCC1 expression did not differ significantly according to HPV status. In multivariate analyses, early T stage (p = 0.036) and good PS (PS 0) (p = 0.029) showed a better 3Y-PFS rate, and low p53 expression (p = 0.012) and complete response after induction chemotherapy (p = 0.026) were highly associated with 3Y-OS rate. Low expression of p53 and p16 positive patients showed significantly prolonged OS than others (p = 0.010). P53, class III beta-tubulin and bcl-2 were differently expressed in OPC according to HPV status and present study suggested the underlying mechanism of better response to chemotherapy in case of HPV OPC than non-HPV OPC. Among these biomarkers, p53 is the strongest prognostic marker in OPC and p53 in addition to p16 support the rationale to study of de-escalation strategy for OPC.Keywords
This publication has 34 references indexed in Scilit:
- Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerBMC Cancer, 2013
- Detection and Typing of Human Papilloma Virus by Multiplex PCR with Type-Specific PrimersISRN Microbiology, 2012
- Next‐generation treatment strategies for human papillomavirus‐related head and neck squamous cell carcinoma: where do we go?Reviews in Medical Virology, 2011
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical ImplicationsClinical Cancer Research, 2009
- Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinomaAnnals of Oncology, 2009
- Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral‐induced carcinoma?International Journal of Cancer, 2009
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysisInternational Journal of Cancer, 2007
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006